What Is Happening With Bristol-Myers Squibb Stock?
Bristol-Myers Squibb (BMY)’s stock sprinted 31%, fueled less by revenue tweaks and more by a leaner margin shine and a soaring valuation. Behind this leap: impressive Q3 beats, fresh FDA nods, and a dividend boost, even as legacy struggles lurk. Let’s unpack what’s really driving the rally.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 10172025 | 1152026 | Change | |
|---|---|---|---|
| Stock Price ($) | 43.1 | 56.6 | 31.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 47,704.0 | 48,034.0 | 0.7% |
| Net Income Margin (%) | 10.6% | 12.6% | 18.8% |
| P/E Multiple | 17.4 | 19.1 | 9.8% |
| Shares Outstanding (Mil) | 2,035.0 | 2,036.0 | -0.0% |
| Cumulative Contribution | 31.3% |
So what is happening here? The stock surged 31%, driven by a modest 0.7% revenue increase, a strong 19% boost in net margin, and a 9.8% rise in the P/E multiple. Let’s dive into what’s behind these moves.
Here Is Why Bristol-Myers Squibb Stock Moved
- Market Leader Bristol-Myers Squibb Stock at 21% Discount, Worth Buying?
- BMY Stock Down -6.3% after 8-Day Loss Streak
- Is Bristol Myers Squibb Undervalued?
- BMY Stock Down -12% after 6-Day Loss Streak
- Is It Time To Buy Bristol Myers Squibb Stock?
- How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
- Q3 2025 Earnings Beat: Reported EPS $1.63 vs est $1.52, revenue beat, raised full-year guidance. Stock climbed 7.1%.
- Strong Growth Portfolio: Q3 2025 Growth Portfolio revenue up 18% to $6.9B, exceeding legacy portfolio.
- Key FDA Approvals: Breyanzi approved for MZL, Opdivo Qvantig approved, Opdivo Hodgkin Lymphoma priority review.
- Legacy Portfolio Woes: Legacy portfolio declined 12% in Q3 2025 due to generic competition for Revlimid.
- Dividend Hike & Upgrade: Increased quarterly dividend by 1.6% to $0.63. Guggenheim upgraded to ‘Buy’.
Our Current Assesment Of BMY Stock
Opinion: We currently find BMY stock fairly priced. Why so? Have a look at the full story. Read Buy or Sell BMY Stock to see what drives our current opinion.
Risk: A good way to gauge risk with BMY is to check how much it fell during major market downturns. The stock dropped about 44% in the Dot-Com Bubble and 43% in the Global Financial Crisis. Even in less severe sell-offs like the 2018 correction and Covid pandemic, it still declined 35% and 31%, respectively. The inflation shock dragged it down over 38%. So, while BMY might seem solid, these numbers remind us that tough market conditions can hit even steady names pretty hard.
BMY stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.